Guinney et al. [29] classified CRC into four consensus molecular subtypes (CMSs): CMS1 tumors characterized by increased expression of genes associated with a diffuse immune infiltrate and features of MSI CRC; CMS2 tumors with strong upregulation of WNT and MYC downstream targets; CMS3 tumors with metabolic pathway dysregulation and KRAS mutations; and CMS4 tumors with clear upregulation of genes involved in the epithelial mesenchymal transition and associated with the activation of TGFβ signaling, angiogenesis, matrix-remodeling pathways, and the complement inflammatory system. Here, KRAS is linked to colorectal carcinoma.